NAPP PHARMACEUTICAL HOLDINGS LIMITED

1. NAPP PHARMACEUTICAL HOLDINGS LIMITED 1998-11-02 → present
2. NAPP PHARMACEUTICALS LIMITED 1997-12-19 → 1998-11-02

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The group's business activities, together with the factors likely to affect its future development are described in the Strategic Report. The group expects to see continued demand for its product portfolio, which notably contains many well-established products treating chronic conditions. The group's latest financial projections show that the group remains in a strong position for the remainder of 2025 through to 31 August 2026. ... Based on this assessment the directors continue to adopt the going concern basis in preparing the annual report and accounts.”

Group structure

1. NAPP PHARMACEUTICAL HOLDINGS LIMITED · parent
   1. Napp Pharmaceutical Group Limited 100% · Supply of pharmaceutical products
   2. Napp Pharmaceuticals Limited 99.6% · Supply of pharmaceutical products
   3. Qdem Pharmaceuticals Limited 99.6% · Supply of pharmaceutical products
   4. Napp Laboratories Limited 100% · Supply of pharmaceutical products
   5. Bard Pharmaceuticals Limited 100% · Manufacture of pharmaceutical products
   6. Napp Research Centre Limited 100% · Non-trading

Significant events

• “In February 2024, NPHL signed an agreement with Xilinx Technology Ltd to assign the remaining lease of Unit 196, Science Park, Milton Road, Cambridge. Following a period of transition, NPHL exited the building in July 2024 and moved to Unit 191.”
• “On 24 April 2024, the Company's subsidiary Napp Pharmaceutical Group Limited acquired all of Cidara Therapeutic's rights related to Rezafungin globally for nil consideration. The subsidiary acquired the rights to future royalties and milestone payments as well as the obligations to fund ongoing development costs. The fair value of net assets acquired was £51,278,000 resulting in negative goodwill of £51,278,000.”
• “On 16 February 2024, the board agreed to increase the original amount on an unsecured revolving loan facility with a related party to £75m from £40m.”
• “On 8 August 2024, the board of subsidiary company Napp Pharmaceutical Group Limited agreed to extend the unsecured loan of $43.5m to a related party to 14 November 2024 and amend the interest rate to 5.83% per annum. The amendments became effective on 14 August 2024. The loan was subsequently repaid on 15 November 2024.”
• “On 14 February 2025, an agreement was made by the group to fully settle a claim from 2016. The final settlement amount was £3,000,000.”
• “On 14 March 2025, subsidiary company Napp Pharmaceuticals Limited received a reimbursement of £4,895,000 from the Department of Health and Social Care in relation to the 2019 Voluntary Scheme phase 1 End of Scheme Reconciliation ('ESR1').”
• “On 28 April 2025, the Board of the Company agreed a loan of £125,000,000 to a related party pursuant to a security agreement and registered charge.”
• “On 02 July 2025, the Board of subsidiary company Napp Laboratories Limited declared an interim dividend distribution of $3,291.29 equivalent to £2,408.91.”
• “On 02 July 2025, the Board of subsidiary company Napp Pharmaceutical Group Limited declared an interim dividend distribution of $6,582.58 equivalent to £4,817.81.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -11%

  £173,745,000 → £154,708,000

• Cash

  +151%

  £63,061,000 → £158,264,000

• Net assets

  +8.8%

  £296,069,000 → £322,070,000

• Employees

  -4.8%

  400 → 381

• Operating profit

  -31.3%

  £39,111,000 → £26,881,000

• Profit before tax

  -16.9%

  £42,846,000 → £35,619,000

• Wages

  -13.6%

  £24,735,000 → £21,369,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers